Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

MLA

William G. Wierda, et al. “Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study.” Blood, vol. 140, Nov. 2022, pp. 846–49. EBSCOhost, https://doi.org/10.1182/blood-2022-157058.

APA

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, … Anthony R. Mato. (2022). Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study. Blood, 140, 846–849. https://doi.org/10.1182/blood-2022-157058

Chicago

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, et al. 2022. “Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study.” Blood 140 (November): 846–49. doi:10.1182/blood-2022-157058.